Publications

Davies S, Boller E, Chase J, Beaubrun A, Miller C, Jensen I. 2024. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J Med Econ 27(1):430–441; doi: 10.1080/13696998.2024.2313391.

Mitchell M, Suh M, Hooda N, Bylsma LC, Cohen S. 2024. The effect of bovine dairy products and their components on the incidence and natural history of infection: A systematic literature review. Nutr J 23(1):26; doi: 10.1186/s12937-024-00923-7. PMID: 38413931.

Suh M, Mitchell M, Hooda N, Bylsma LC, Cohen SS. 2024. The effects of dairy consumption on vaccine immune response and immunoglobulins: A systematic literature review. Int J Nutr 8(1):1–25; doi: 10.14302/issn.2379-7835.ijn-24-4938.

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; doi :10.1016/j.annonc.2023.10.262.

Movva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. PLoS One 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125. ISPOR EU 2023.

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547. ISPOR EU 2023.